摘要
目的:探究他克莫司在特发性膜性肾病患者免疫学缓解与临床缓解中的效果。方法:选择2020年7月-2021年12月清远市人民医院收治的80例特发性膜性肾病患者为研究对象,根据随机数表法将其分为两组,各40例。对照组予以环磷酰胺联合泼尼松治疗,观察组予以他克莫司联合泼尼松治疗。比较两组临床缓解率、免疫学缓解率、治疗前后的抗磷脂酶A2受体抗体(aPLA2R)、尿蛋白、血清白蛋白、血脂指标[甘油三酯(TG)及总胆固醇(TC)]水平及复发率、不良反应发生率。结果:观察组临床总缓解率高于对照组,复发率及不良反应总发生率均低于对照组,差异有统计学意义(P<0.05)。治疗1个月、3个月及6个月后,观察组免疫学缓解率均高于对照组,差异有统计学意义(P<0.05)。治疗前,两组aPLA2R、尿蛋白、血清白蛋白及血脂指标比较,差异无统计学意义(P>0.05)。治疗1个月、3个月及6个月后,观察组血清白蛋白显著高于对照组,aPLA2R、尿蛋白及血脂指标则均显著低于对照组,差异有统计学意义(P<0.05)。结论:他克莫司联合泼尼松治疗特发性膜性肾病患者的效果较好,能提高免疫学缓解率与临床缓解率,且安全性较高。
Objective:To explore the effect of Tacrolimus on immunological remission and clinical remission in patients with idiopathic membranous nephropathy.Method:A total of 80 patients with idiopathic membranous nephropathy in Qingyuan People's Hospital from July 2020 to December 2021 were divided into two groups with by the random number table,40 cases in each group.The control group were treated with Cyclophosphamide combined with Prednisone,the observation group were treated with Tacrolimus combined with Prednisone.The clinical remission rate,immunological remission rate,the levels of anti phospholipase A2 receptor antibody(aPLA2R),urinary protein,serum albumin,blood lipid indicators[triglyceride(TG)and total cholesterol(TC)]before and after treatment,recurrence rate and adverse reaction rate were compared between the two groups.Result:The total clinical remission rate of the observation group was higher than that of the control group,while the recurrence rate and total incidence of adverse reactions were lower than those of the control group,the differences were statistically significant(P<0.05).After 1 month,3 months,and 6 months of treatment,the immunological response rate of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences between the two groups in terms of aPLA2R,urinary protein,serum albumin,and blood lipid indicators(P>0.05).After 1 month,3 months,and 6 months of treatment,the serum albumin of the observation group was significantly higher than that of the control group,while the aPLA2R,urinary protein,and blood lipid indicators were significantly lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:Tacrolimus combined with Prednisone is effective in the treatment of idiopathic membranous nephropathy,which can improve the immunological response rate and clinical response rate,and has high safety.
作者
罗成建
胡俊恒
LUO Chengjian;HU Junheng(Qingyuan People's Hospital,Qingyuan 511500,China;不详)
出处
《中外医学研究》
2023年第22期33-36,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
清远市科技计划项目(190925094560523)。
关键词
他克莫司
特发性膜性肾病
免疫学缓解
临床缓解
Tacrolimus
Idiopathic membranous nephropathy
Immunological remission
Clinical remission
